tbuckley/cabot-search huggingface dataset:
Training for Effective Patient Communication
Authors: Yvo Smulders
Journal: JAMA (2014)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Selective FLT3 Inhibitor FI-700 Neutralizes Mcl-1 and Enhances p53-Mediated Apoptosis in Acute Myeloid Leukemia (AML) Cells with Activating Mutations of FLT3 Via Mcl-1/Noxa Axis.
Authors: Kensuke Kojima, Marina Konopleva, Twee Tsao, Michael Andreeff, Hiroshi Ishida, Yukimasa Shiotsu, Linhua Jin, Yoko Tabe, Hideki Nakakuma
Journal: Blood (2009)
Foxp2 controls synaptic wiring of corticostriatal circuits and vocal communication by opposing Mef2c
Authors: Yi-Chuan Chen, Hsiao-Ying Kuo, Ulrich Bornschein, Hiroshi Takahashi, Shih-Yun Chen, Kuan-Ming Lu, Hao-Yu Yang, Gui-May Chen, Jing-Ruei Lin, Yi-Hsin Lee, Yun-Chia Chou, Sin-Jhong Cheng, Cheng-Ting Chien, Wolfgang Enard, Wulf Hevers, Svante Pääbo, Ann M Graybiel, Fu-Chin Liu
Journal: Nature Neuroscience (2016)
iNKT Cells Induce FGF21 for Thermogenesis and Are Required for Maximal Weight Loss in GLP1 Therapy
Authors: Lydia Lynch, Andrew E. Hogan, Danielle Duquette, Chantel Lester, Alexander Banks, Katherine LeClair, David E. Cohen, Abhisek Ghosh, Bing Lu, Michelle Corrigan, Darko Stevanovic, Eleftheria Maratos-Flier, Daniel J. Drucker, Donal O’Shea, Michael Brenner
Journal: Cell Metabolism (2016)
On the US Preventive Services Task Force Statement on Screening for Lipid Disorders in Children and Adolescents
Authors: Stephen R. Daniels
Journal: JAMA Pediatrics (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Epidermoid anal cancer: Results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin
Authors: S J Arnott, D Cunningham, J Gallagher, R Gray, J Hardcastle, J Houghton, R D James, T A Lennon, H M Meadows, J Mossman, Northover Jma., Morgan Dal., P N Plowman, M Slevin
Journal: The Lancet (1996)
Lymphocyte-to-Monocyte Ratio at Diagnosis and Survival in De Novo Double/Triple Hit Diffuse Large B-Cell Lymphoma
Authors: Luis Porrata, Kay Ristow, Ellen D. McPhail, William Macon, Matthew J Maurer, Grzegorz S. Nowakowski, Stephen Ansell, Thomas E. Witzig, Svetomir Markovic, Thomas M. Habermann
Journal: Blood (2015)
Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
Authors: P I Croucher, C M Shipman, M J Perry, J Lippitt, K Asosingh, van Beek Ejr., B Van Camp, G G Russell, C Dunstan, K Vanderkerken
Journal: Blood (2000)
Brief Report: Course of Active Inflammatory and Fatty Lesions in Patients With Early Axial Spondyloarthritis Treated With Infliximab Plus Naproxen as Compared to Naproxen Alone: Results From the Infliximab As First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial
Authors: Denis Poddubnyy, Joachim Listing, Joachim Sieper
Journal: Arthritis & Rheumatology (2016)

To investigate the course of active inflammatory and fatty lesions seen on magnetic resonance imaging (MRI) in patients with early axial spondyloarthritis (SpA) treated with the tumor necrosis factor (TNF) inhibitor infliximab added to naproxen as compared to those treated with naproxen alone.A total of 158 patients with active axial SpA were randomized (2:1) to receive 28 weeks of treatment with either infliximab 5 mg/kg plus naproxen 1,000 mg/day or placebo plus naproxen 1,000 mg/day. MRI of the sacroiliac (SI) joints and of the spine was performed at baseline and week 28. Images were scored for active inflammation and for fatty lesions.After 28 weeks, there was a significant reduction of inflammation in the spine and in the SI joints in both treatment groups, which was, however, more prominent in the infliximab plus naproxen group (mean ± SD spine osteitis change score -2.9 ± 5.1, versus -2.0 ± 4.2 in the placebo plus naproxen group [P < 0.001]; SI joint osteitis change score -4.3 ± 5.2 in the infliximab plus naproxen group versus -3.9 ± 3.7 in the placebo plus naproxen group [P = 0.003]). Similarly, there was a significant increase in the fatty lesion score after 28 weeks in both groups; this change did not, however, differ significantly between groups (spine fatty lesion change score 0.8 ± 1.7 in the infliximab plus naproxen group versus 1.0 ± 1.8 in the placebo plus naproxen group [P = 0.72]; SI joint fatty lesion change score 1.7 ± 2.7 in the infliximab plus naproxen group versus 1.4 ± 2.6 in the placebo plus naproxen group [P = 0.86]).These findings indicate that effective antiinflammatory treatment of axial SpA is associated with an increase in fatty lesion scores, independent of concomitant treatment with or without anti-TNF.
<i>Helicobacter pylori-</i>induced cell death is counteracted by NF-κB-mediated transcription of DARPP-32
Authors: Shoumin Zhu, Mohammed Soutto, Zheng Chen, DunFa Peng, Judith Romero-Gallo, Uma S Krishna, Abbes Belkhiri, M Kay Washington, Richard Peek, Wael El-Rifai
Journal: Gut (2016)

DARPP-32 is a frequently amplified and overexpressed gene that promotes several oncogenic functions in gastric cancer. Herein, we investigated the relationship between Helicobacter pylori infection, proinflammatory NF-κB activation and regulation of DARPP-32.The study used in vivo and in vitro experiments. Luciferase reporter, quantitative real-time PCR, immunoblot, chromatin immunoprecipitation (ChIP), cell viability, H. pylori infection, tissue microarrays and immunohistochemical assays were used.Our results indicated that H. pylori infection increased the DARPP-32 mRNA and protein levels in gastric cancer cell lines and gastric mucosa of mice. H. pylori infection increased the activity of NF-κB reporter and p-NF-κB (S536) protein level in vitro and in vivo. To investigate the transcriptional regulation of DARPP-32, we cloned a 3019 bp of the DARPP-32 promoter into the luciferase reporter (pGL3-Luc). Both H. pylori infection and tumour necrosis factor-α treatment induced DARPP-32 reporter activity (p<0.01). Using deletion constructs of DARPP-32 promoter and ChIP assay, we demonstrated that the sequence -996 to -1008 bp containing putative NF-κB-binding sites is the most active region. The induction of DARPP-32 expression by H. pylori infection counteracted H. pylori-induced cell death through activation of serine/threonine-specific protein kinase (AKT), as determined by ATP-Glo and clonogenic survival assays. Immunohistochemistry analysis demonstrated a significant positive correlation between NF-κB and DARPP-32 expression levels in gastric cancer tissues (r2=0.43, p<0.01).Given the high frequency of DARPP-32 overexpression and its prosurvival oncogenic functions, the induction of DARPP-32 expression following H. pylori infection and activation of NF-κB provides a link between infection, inflammation and gastric tumourigenesis.
Changes in the T and B- Cell Subsets Following Treatment with a CD25-Antibody in Patients with Steroid Refractory GvHD
Authors: Geothy Chakupurakal, Maria Garcia- Marquez, Alexander Shimabukuro- Vornhagen, Hans Anton Schloesser, Udo Holtick, Christoph Scheid, Michael von Bergwelt-Baildon
Journal: Blood (2014)
Probiotic supplementation has little effect on peripheral blood regulatory T cells
Authors: Nicholas P. West, Peggy L. Horn, David B. Pyne, Hilary S. Warren, Suzanne Asad, Amanda J. Cox, Sampo J. Lahtinen, Markus J. Lehtinen, Peter A. Fricker, Allan W. Cripps, Barbara Fazekas de St Groth
Journal: Journal of Allergy and Clinical Immunology (2016)
Efficacy of the combination of irinotecan and bevacizumab in heavely pretreated metastatic breast cancer
Authors: J. Espinós, C. Olier-Garate, J. M. Aramendia, O. Fernandez Hidalgo, C. Reyna, S. De la Cruz, A. del Barrio, J. García-Foncillas
Journal: Journal of Clinical Oncology (2008)

12001 Background: The level of angiogenic activity in breast cancer has been shown to be a determinant of disease progression. Adding an antiangiogenic agent to chemotherapy has demonstrated to improve disease free survival and overall survival in patients diagnosed of metastatic breast cancer. We present a retrospective analysis of patients treated at our institution with bevacizumab plus irinotecan based chemotherapy. Methods: Pretreated patients with metastatic breast cancer received bevacizumab in combination with chemotherapy. Toxicity was graded according to the NCI Common Toxicity Criteria and response was evaluated using the RECIST criteria and biochemical parameters. Results: A total of 15 patients diagnosed of metastatic breast cancer were included. The median of age was 55 years. The 93.3% had bone metastases, the 80% showed liver disease, 46.7% had pulmonary metastases and the 6.7% had CNS metastases. They were treated from february 2005 to january 2007. They received a median of 6 cycles (1–26). All patients but one received bevacizumab (10 mg/kg) in combination with irinotecan (150 mg/m2) every 2 weeks, the other patient received bevacizumab (10 mg/kg) in combination with Irinotecan (150 mg/m2) and oxaliplatin (85 mg/m2). They received a median of 4.5 previous lines. We obtained 46% of stable disease and 13.3% of partial responses. Median time to progression was 5 months (0–10,4) and overall survival was 7 months (3.2–10.7). Grade 3 adverse effects were fatigue (1 patient), diarrhoea (1), 1 patient had grade 3 anemia, another grade 3 leucopenia, and one patient had grade 3 trombopenia. Grade 4 adverse events included diarrhea (1), vomiting (1) and hematologic toxicity (one patient with grade 4 trombopenia). We registered no tromboembolic events and in 6 patients (40%) we observed grade 1 bleeding (epistaxis). There were no toxic deaths. Conclusions: Bevacizumab in combination with chemotherapy seems to be well tolerated and active in patients with metastatic breast cancer, after several previous regimens of chemotherapy. No significant financial relationships to disclose.
Safety and activity of nivolumab (nivo) monotherapy and nivo in combination with ipilimumab (ipi) in recurrent glioblastoma (GBM): Updated results from checkmate-143.
Authors: David A. Reardon, John H. Sampson, Solmaz Sahebjam, Michael Lim, Joachim M. Baehring, Gordana Vlahovic, Timothy Francis Cloughesy, Lewis C. Strauss, Robert Raymond Latek, Prashni Paliwal, Christopher T. Harbison, Alfredo Daniel Voloschin, Antonio Marcilio Padula Omuro
Journal: Journal of Clinical Oncology (2016)

2014 Background: Patients (pts) with recurrent/progressive GBM have a poor prognosis and limited therapeutic options. The phase 1 CheckMate-143 study evaluates safety and tolerability of the anti-PD-1 monoclonal antibody nivo, alone or in combination with the anti-CTLA-4 antibody ipi, in pts with recurrent GBM. Preliminary results from a phase 1 safety cohort (Cohort 1, Methods) were presented previously. Herein, we present updated safety, overall survival (OS) data, and PD-L1 biomarker status for the completed phase 1 Cohorts 1 and 1b. Methods: Eligible pts had a first recurrence of GBM after radiation and temozolomide. In Cohort 1, 20 pts were randomized 1:1 to receive nivo 3 mg/kg (N3) every 2 weeks (Q2W) or nivo 1 mg/kg + ipi 3 mg/kg every 3 weeks (Q3W; N1+I3) for 4 doses followed by N3 Q2W. Pts in Cohort 1b (n = 20) received nivo 3 mg/kg + ipi 1 mg/kg Q3W (N3+I1) for 4 doses followed by N3 Q2W. Treatment continued until disease progression or unacceptable toxicity. PD-L1 status was determined by immunohistochemistry. Results: Accrual to Cohorts 1 and 1b was completed (N = 40). Median ages were 59 (range: 42–73), 55 (37–68), and 55 (27–73) years in the N3, N1+I3, and N3+I1 arms, respectively. Median Karnofsky performance status (N = 40) was 90 (range: 70–90). Treatment-related adverse events (TRAEs) and treatment-related serious AEs (TRSAEs) are summarized (Table). Three pts on N1 + I3, 1 pt on N3 + I1, and 0 pts receiving N3 discontinued for TRAEs. Stable disease or better was achieved in 6/10, 4/10, and 9/20 pts receiving N3, N1+I3, and N3+I1, respectively. The 12-month OS was 40% (95% CI: 12–67) for N3, 30% (95% CI: 7–58) for N1+I3, and 25% (95% CI: 8–48) for N3+I1. PD-L1 expression was quantifiable in 34 pts (85%). Conclusions: Tolerability profiles in pts receiving nivo and nivo + ipi are consistent with observations in other tumor types, with no new safety signals. N3 was the best tolerated, and N3+I1 was better tolerated than N1+I3. Twelve-month OS rates are encouraging. Clinical trial information: NCT02017717. Cohort 1 Cohort 1b AEs, n (%) N3 (n = 10) N1+I3 (n = 10) N3+I1 (n = 20) TRAEs Any grade 9 (90) 10 (100) 20 (100) Grade 3–4 0 9 (90) 5 (25) Grade 5 0 0 0 TRSAEs Any grade 2 (20) 7 (70) 5 (25) Grade 3–4 0 7 (70) 2 (10) Grade 5 0 0 0
Factors shaping the composition of the cutaneous microbiota
Authors: K. Szabó, L. Erdei, B. Sz. Bolla, G. Tax, T. Bíró, L. Kemény
Journal: British Journal of Dermatology (2016)

From birth, we are constantly exposed to bacteria, fungi and viruses, some of which are capable of transiently or permanently inhabiting our different body parts as our microbiota. The majority of our microbial interactions occur during and after birth, and several different factors, including age, sex, genetic constitution, environmental conditions and lifestyle, have been suggested to shape the composition of this microbial community. Propionibacterium acnes is one of the most dominant lipophilic microbes of the postadolescent, sebum‐rich human skin regions. Currently, the role of this bacterium in the pathogenesis of the most common inflammatory skin disease, acne vulgaris, is a topic of intense scientific debate. Recent results suggest that Westernization strongly increases the dominance of the Propionibacterium genus in human skin compared with natural populations living more traditional lifestyles. According to the disappearing microbiota hypothesis proposed by Martin Blaser, such alterations in the composition of our microbiota are the possible consequences of socioeconomic and lifestyle changes occurring after the industrial revolution. Evanescence of species that are important elements of the human ecosystem might lead to the overgrowth and subsequent dominance of others because of the lack of ecological competition. Such changes can disturb the fine‐tuned balance of the human body and, accordingly, our microbes developed through a long co‐evolutionary process. These processes might lead to the transformation of a seemingly harmless species into an opportunistic pathogen through bacterial dysbiosis. This might have happened in the case of P. acnes in acne pathogenesis.
MNX1 Is Oncogenically Upregulated in African-American Prostate Cancer
Authors: Li Zhang, Jianghua Wang, Yongquan Wang, Yiqun Zhang, Patricia Castro, Longjiang Shao, Arun Sreekumar, Nagireddy Putluri, Nilanjan Guha, Saligrama Deepak, Arunkumar Padmanaban, Chad J. Creighton, Michael Ittmann
Journal: Cancer Research (2016)

Abstract Incidence and mortality rates for prostate cancer are higher in African-American (AA) men than in European-American (EA) men, but the biologic basis for this disparity is unclear. We carried out a detailed analysis of gene expression changes in prostate cancer compared with their matched benign tissues in a cohort of AA men and compared them with existing data from EA men. In this manner, we identified MNX1 as a novel oncogene upregulated to a relatively greater degree in prostate cancer from AA men. Androgen and AKT signaling play a central role in the pathogenesis of prostate cancer and we found that both of these signaling pathways increased MNX1 expression. MNX1 in turn upregulated lipid synthesis by stimulating expression of SREBP1 and fatty acid synthetase. Our results define MNX1 as a novel targetable oncogene increased in AA prostate cancer that is associated with aggressive disease. Cancer Res; 76(21); 6290–8. ©2016 AACR.
Faster for less: the new “shorter” regimen for multidrug-resistant tuberculosis
Authors: Giovanni Sotgiu, Simon Tiberi, Lia D'Ambrosio, Rosella Centis, Jan Willem Alffenaar, Jose A. Caminero, Marcos Abdo Arbex, Valentina Alarcon Guizado, Alena Aleksa, Simone Dore, Mina Gaga, Gina Gualano, Heinke Kunst, Marie-Christine Payen, Aurora Jazmín Roby Arias, Alena Skrahina, Ivan Solovic, Giorgia Sulis, Marina Tadolini, Alimuddin Zumla, Giovanni Battista Migliori
Journal: European Respiratory Journal (2016)

Multidrug resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) are growing clinical and public health concerns, with an estimated worldwide incidence and mortality of 480 000 and 190 000 cases, respectively (2014) [1]. The World Health Organization (WHO) End TB Strategy reiterates the MDR-/XDR-TB threat and the solutions to control the epidemic [2]. Unfortunately, large proportions of patients with resistant TB do not have access to adequate diagnostics and treatment yet, while treatment success rates remain suboptimal (as demonstrated in the largest retrospective cohort of MDR-TB patients, i.e. , TB caused by Mycobacterium tuberculosis isolates resistant to at least isoniazid and rifampicin) and decrease further with resistance patterns beyond XDR-TB [3]. Evaluation of drug resistances is needed to identify candidates for the shorter regimen in MDR-TB hot spots <http://ow.ly/wZV33022VXt> The authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions and policies of their institutions. All authors contributed to the conception of the study, data analysis, interpretation of the results, drafting of the manuscript and approval of the final version. Members of the International Carbapenem Study Group: M. Abdo Arbex (Brazil), O.W. Akkerman (The Netherlands), E. Alarcon Arrascue (Peru), V. Alarcon Guizado (Peru), A. Aleksa (Belarus), J.W. Alffenaar (The Netherlands), J. Artsukevich (Belarus), V. Avchynka (Belarus), J.A. Caminero (Spain), R. Centis (Italy), L. D'Ambrosio (Italy), S. De Lorenzo (Italy), S. Dore (Italy), M. Gaga (Greece), G. Gualano (Italy), A.J. Roby Arias (Ecuador), E.H. Bonini (Brazil), F.A. Chong Marín (Ecuador), G. de Vries (The Netherlands), S. Dore (Italy), H. Kunst (UK), A. Matteelli (Italy), G.B. Migliori (Italy), C. Moschos (Greece), F. Palmieri (Italy), A. Papavasileiou (Greece), M.C. Payen (Belgium), A. Piana (Italy), A. Scardigli (France), A. Skrahina (Belarus), I. Solovic (Slovakia), G. Sotgiu (Italy), A. Spanevello (Italy), G. Sulis (Italy), M. Tadolini (Italy), S. Tiberi (UK), D. Vargas Vasquez (Peru), P. Viggiani (Italy), V. White (UK), A. Zumla (UK).
Parental Psychiatric Disease and Risks of Attempted Suicide and Violent Criminal Offending in Offspring
Authors: Pearl L. H. Mok, Carsten Bøcker Pedersen, David Springate, Aske Astrup, Nav Kapur, Sussie Antonsen, Ole Mors, Roger T. Webb
Journal: JAMA Psychiatry (2016)

Self-directed and interpersonal violence share some common risk factors such as a parental history of mental illness. However, relationships between the full spectrum of parental psychiatric disease and these 2 related outcomes are unclear.To examine associations between the full spectrum of parental psychiatric disease and risks of attempted suicide and violent offending among offspring.Population-based cohort study of all persons born in Denmark 1967 through 1997, followed up from their 15th birthday until occurrence of adverse outcome or December 31, 2012, whichever came first.Array of parental psychiatric disorders and parental suicide attempt, delineated from records of secondary care treatments.Using survival analyses techniques, incidence rate ratios were estimated for offspring suicide attempt and violent offending.We examined 1 743 525 cohort members (48.7% female; total follow-up, 27.2 million person-years). Risks for offspring suicide attempt and violent offending were elevated across virtually the full spectrum of parental psychiatric disease. Incidence rate ratios were the most elevated for parental diagnoses of antisocial personality disorder (suicide attempt, 3.96; 95% CI, 3.72-4.21; violent offending, 3.62; 95% CI, 3.41-3.84) and cannabis misuse (suicide attempt, 3.57; 95% CI, 3.25-3.92; violent offending, 4.05; 95% CI, 3.72-4.39), and for parental suicide attempt (suicide attempt, 3.42; 95% CI, 3.29-3.55; violent offending, 3.31; 95% CI, 3.19-3.44). Parental mood disorders (and bipolar disorder in particular) conferred more modest risk increases. A history of mental illness or suicide attempt in both parents was associated with double the risks compared with having just 1 affected parent. Associations between parental psychiatric disease and offspring violent offending were stronger for female than for male offspring, whereas little sex difference in risk was found for offspring suicide attempt.The similarities in risk patterns observed between the 2 outcomes may evidence a shared etiology. Early interventions to tackle parental mental disorders may be beneficial to both parents and children.